Increasing Prevalence of Addison Disease: Results From a Nationwide Study
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2016-01
Metadata
Show full item recordCitation
Increasing Prevalence of Addison Disease: Results From a Nationwide Study. 2016, 22 (1):30-5 Endocr PractAbstract
Primary adrenal insufficiency is a life-threatening endocrine disease unless properly treated. However, few studies on the prevalence, concomitances of the disease, and prescribing of drugs have been published. The goal of the study was to establish the prevalence of primary adrenal insufficiency in Iceland and additionally, to study the most common concomitant diseases in patients with primary adrenal insufficiency, as well as the mode of glucocorticoid replacement therapies.To achieve this, the medical records of all patients in Iceland who had received the International Classification of Diseases and Related Health Problems, 10th Revision, diagnosis code E27, were evaluated for true primary adrenal insufficiency. Additionally, these records were evaluated for concomitant diseases, as well as the mode of glucocorticoid replacement therapy. The study covered the whole population of Iceland over 18 years of age. It was thus a nationwide study. The records were retrieved from large hospitals and clinics and every practicing specialist in endocrinology.
Primary adrenal insufficiency was found in 53 individuals, 26 women and 27 men, yielding a prevalence of 22.1 per 100,000 population. Hypothyroidism was by far the most common concomitant disease. Most patients had their glucocorticoid deficiency replaced with short-acting glucocorticoids.
The prevalence of primary adrenal insufficiency in Iceland is higher than in earlier reports, with comorbidities being in line with recent studies. Treatment is according to the latest protocols.
Description
To access publisher's full text version of this article click on the hyperlink at the bottom of the pageAdditional Links
http://dx.doi.org/ 10.4158/EP15754.ORRights
Archived with thanks to Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistsae974a485f413a2113503eed53cd6c53
10.4158/EP15754.OR
Scopus Count
Collections
Related articles
- Primary adrenal insufficiency in the United States: diagnostic error and patient satisfaction with treatment.
- Authors: Regan EA, Vaidya A, Margulies PL, Make BJ, Lowe KE, Crapo JD
- Issue date: 2019 Nov 26
- Clinical and Immunological Characteristics of Autoimmune Addison Disease: A Nationwide Swedish Multicenter Study.
- Authors: Dalin F, Nordling Eriksson G, Dahlqvist P, Hallgren Å, Wahlberg J, Ekwall O, Söderberg S, Rönnelid J, Olcén P, Winqvist O, Catrina SB, Kriström B, Laudius M, Isaksson M, Halldin Stenlid M, Gustafsson J, Gebre-Medhin G, Björnsdottir S, Janson A, Åkerman AK, Åman J, Duchen K, Bergthorsdottir R, Johannsson G, Lindskog E, Landin-Olsson M, Elfving M, Waldenström E, Hulting AL, Kämpe O, Bensing S
- Issue date: 2017 Feb 1
- Health-related quality of life in primary and secondary adrenal insufficiency.
- Authors: Aulinas A, Webb SM
- Issue date: 2014 Dec
- Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy.
- Authors: Dineen R, Stewart PM, Sherlock M
- Issue date: 2019 Jan
- Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.
- Authors: Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Ragnarsson O, Skrtic S, Wahlberg J, Achenbach H, Uddin S, Marelli C, Johannsson G
- Issue date: 2017 Jun